Marion v. Searle
In a Sept. 25 complaint, Cardizem manufacturer asked Kansas City, Mo. Federal Court for injunction against comparative ads with "false, misleading and deceptive" claims that Searle's Calan dosage is 240 mg per day, whereas Cardizem's is 180 mg twice daily. Marion argues that Calan is prescribed at "higher than 240 mg per day" while Cardizem's dosage is 90 mg b.i.d.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.